title: Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.
abstract: Mucopolysaccharidosis type IVA (MPS IVA) was described in 1929 by Luis Morquio from Uruguay and James Brailsford from England, and was later found as an autosomal recessive lysosomal storage disease. MPS IVA is caused by mutations in the gene encoding the enzyme, N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Reduced GALNS activity results in impaired catabolism of two glycosaminoglycans (GAGs), chondroitin-6-sulfate (C6S) and keratan sulfate (KS). Clinical presentations of MPS IVA reflect a spectrum of progression from a severe "classical" phenotype to a mild "attenuated" phenotype. More than 180 different mutations have been identified in the GALNS gene, which likely explains the phenotypic heterogeneity of the disorder. Accumulation of C6S and KS manifests predominantly as short stature and skeletal dysplasia (dysostosis multiplex), including atlantoaxial instability and cervical cord compression. However, abnormalities in the visual, auditory, cardiovascular, and respiratory systems can also affect individuals with MPS IVA. Diagnosis is typically based on clinical examination, skeletal radiographs, urinary GAG, and enzymatic activity of GALNS in blood cells or fibroblasts. Deficiency of GALNS activity is a common assessment for the laboratory diagnosis of MPS IVA; however, with recently increased availability, gene sequencing for MPS IVA is often used to confirm enzyme results. As multiple clinical presentations are observed, diagnosis of MPS IVA may require multi-system considerations. This review provides a history of defining MPS IVA and how the understanding of the disease manifestations has changed over time. A summary of the accumulated knowledge is presented, including information from the International Morquio Registry. The classical phenotype is contrasted with attenuated cases, which are now being recognized and diagnosed more frequently. Laboratory based diagnoses of MPS IVA are also discussed.
authors.affiliation: University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Hendriksz
authors.forename: P
authors.initials: P
authors.lastname: Harmatz
authors.forename: M
authors.initials: M
authors.lastname: Beck
authors.forename: S
authors.initials: S
authors.lastname: Jones
authors.forename: T
authors.initials: T
authors.lastname: Wood
authors.forename: R
authors.initials: R
authors.lastname: Lachman
authors.forename: C G
authors.initials: CG
authors.lastname: Gravance
authors.forename: T
authors.initials: T
authors.lastname: Orii
authors.forename: S
authors.initials: S
authors.lastname: Tomatsu
mesh_terms: D002811:Chondroitinsulfatases / Q000235:genetics*; D005347:Fibroblasts / Q000201:enzymology / Q000378:metabolism; D006025:Glycosaminoglycans / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009085:Mucopolysaccharidosis IV / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D010641:Phenotype
chemical_list: D006025:Glycosaminoglycans; D002811:Chondroitinsulfatases; C102295:GALNS protein, human
keywords: CDC; CPAP; Centers for Disease Control and Prevention; Continuous positive airway pressure; DBS; Dried blood spots; GALNS; Laboratory diagnosis; MPS IVA; Morquio A; Mucopolysaccharidosis IVA; N-acetylgalactosamine-6-sulfate sulfatase